SARS-CoV-2 in Stools Compared to Respiratory Viral Strains.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-30

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to characterize and to quantify SARS-CoV-2 strains in stools, in comparison with the viral strains in respiratory samples, from patients hospitalized for COVID-19. The methods will be standard ddPCR quantifying SARS-CoV-2 RNA and next generation sequencing-whole genome sequencing. The expected results will allow us to better understand SARS-CoV-2 dynamics and compartmentalization, both in the respiratory tract and in digestive-related tissues, according to the evolution of SARS-CoV-2 variants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 Persistence in Stool

NCT04546776

SARS-CoV Infection

COMPLETED

Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of Patients With COVID-19.

NCT05107245

COVID-19

COMPLETED

Intestinal Microbiota of Patients Hospitalized With Sars-CoV-2

NCT05178238

COVID-19

ACTIVE_NOT_RECRUITING

Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms

NCT06524791

Gastroenteritis

NOT_YET_RECRUITING

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

NCT01232595

Moderate Clostridium Difficile Infection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological assays

PCR and NGS-WGS on stools and respiratory samples

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: men or women of 18 years-old or more
* Clinical signs: hospitalised patient for SARS-CoV-2 infection, nasopharyngeal PCR-confirmed (or any other sample) (in: Infectious diseases department, Intensive care unit), whatever the severity of the clinical form.
* The subject gave his/her informed and writen consent, after complete explanations on the research schedule.
* Compulsory affiliation to a social security scheme.
* Previous medical examination, when a patient is admitted to the hospital, according to good clinical practices.

Exclusion Criteria

* Subject corresponding to articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public health code:

* pregnant woman, parturient or breastfeeding woman
* Minor person
* Person of full age under guardianship, curatorship, safeguard of justice
* Woman who wants to be pregnant during the study period
* Person in psychiatric care - articles L. 3212-1 and L. 3213-1 who do not fall under the article L. 1121-8 (without consent hospitalisation)

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No